JP2016504358A - オキシブチニンを投与するための方法および組成物 - Google Patents

オキシブチニンを投与するための方法および組成物 Download PDF

Info

Publication number: JP2016504358A
Authority: JP; Japan
Prior art keywords: oxybutynin; vitamin; xinafoate; lung; dry powder
Prior art date: 2012-12-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2015550444A

Other languages

English (en)

Japanese (ja)

Inventor

クック，ロバート

バイロン，デービッド，エイ．

フレミング，スコット

Original Assignee

マイクロドースセラピューテクス，インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-27

Filing date

2013-12-12

Publication date

2016-02-12

2012-12-27 Priority claimed from US13/728,706 external-priority patent/US9119777B2/en

2013-12-12 Application filed by マイクロドースセラピューテクス，インコーポレイテッド, マイクロドースセラピューテクス，インコーポレイテッド filed Critical マイクロドースセラピューテクス，インコーポレイテッド

2016-02-12 Publication of JP2016504358A publication Critical patent/JP2016504358A/ja

Status Pending legal-status Critical Current

Links

XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 title claims abstract description 162
229960005434 oxybutynin Drugs 0.000 title claims abstract description 151
238000000034 method Methods 0.000 title claims abstract description 37
239000000203 mixture Substances 0.000 title abstract description 28
210000004072 lung Anatomy 0.000 claims abstract description 31
229950000339 xinafoate Drugs 0.000 claims abstract description 28
150000003839 salts Chemical class 0.000 claims abstract description 27
239000003795 chemical substances by application Substances 0.000 claims abstract description 25
239000000126 substance Substances 0.000 claims abstract description 25
208000019693 Lung disease Diseases 0.000 claims abstract description 17
239000003246 corticosteroid Substances 0.000 claims abstract description 17
229940124630 bronchodilator Drugs 0.000 claims abstract description 11
230000002062 proliferating effect Effects 0.000 claims abstract description 10
229960001334 corticosteroids Drugs 0.000 claims abstract description 7
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims abstract description 7
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims abstract description 6
229940070765 laurate Drugs 0.000 claims abstract description 6
229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 5
239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 5
239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 4
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 23
239000000843 powder Substances 0.000 claims description 23
239000002245 particle Substances 0.000 claims description 19
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 18
102000003702 retinoic acid receptors Human genes 0.000 claims description 18
108090000064 retinoic acid receptors Proteins 0.000 claims description 18
235000019166 vitamin D Nutrition 0.000 claims description 18
239000011710 vitamin D Substances 0.000 claims description 18
229930003316 Vitamin D Natural products 0.000 claims description 17
150000003710 vitamin D derivatives Chemical class 0.000 claims description 17
229940046008 vitamin d Drugs 0.000 claims description 17
239000012313 reversal agent Substances 0.000 claims description 13
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 12
229940112141 dry powder inhaler Drugs 0.000 claims description 11
229930002330 retinoic acid Natural products 0.000 claims description 11
208000006673 asthma Diseases 0.000 claims description 10
230000015572 biosynthetic process Effects 0.000 claims description 10
239000003112 inhibitor Substances 0.000 claims description 9
102000009310 vitamin D receptors Human genes 0.000 claims description 9
108050000156 vitamin D receptors Proteins 0.000 claims description 9
239000013543 active substance Substances 0.000 claims description 8
229940125369 inhaled corticosteroids Drugs 0.000 claims description 8
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 8
MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 8
239000000556 agonist Substances 0.000 claims description 7
229960002848 formoterol Drugs 0.000 claims description 7
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 7
229940044601 receptor agonist Drugs 0.000 claims description 7
239000000018 receptor agonist Substances 0.000 claims description 7
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 6
229960004436 budesonide Drugs 0.000 claims description 6
235000020964 calcitriol Nutrition 0.000 claims description 6
239000011612 calcitriol Substances 0.000 claims description 6
229960005084 calcitriol Drugs 0.000 claims description 6
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 6
229960002714 fluticasone Drugs 0.000 claims description 6
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 6
229940071648 metered dose inhaler Drugs 0.000 claims description 6
IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 claims description 5
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 5
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 5
229950010713 carmoterol Drugs 0.000 claims description 5
229960003728 ciclesonide Drugs 0.000 claims description 5
229960001798 loteprednol Drugs 0.000 claims description 5
YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims description 5
229960001664 mometasone Drugs 0.000 claims description 5
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 5
COUYJEVMBVSIHV-SFHVURJKSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-SFHVURJKSA-N 0.000 claims description 5
229960004286 olodaterol Drugs 0.000 claims description 5
229960004017 salmeterol Drugs 0.000 claims description 5
238000003786 synthesis reaction Methods 0.000 claims description 5
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
206010014561 Emphysema Diseases 0.000 claims description 4
102000011779 Nitric Oxide Synthase Type II Human genes 0.000 claims description 4
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 claims description 4
206010035664 Pneumonia Diseases 0.000 claims description 4
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
206010006451 bronchitis Diseases 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
229940041033 macrolides Drugs 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
229960000278 theophylline Drugs 0.000 claims description 4
235000019155 vitamin A Nutrition 0.000 claims description 4
239000011719 vitamin A Substances 0.000 claims description 4
229940045997 vitamin a Drugs 0.000 claims description 4
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 3
239000012825 JNK inhibitor Substances 0.000 claims description 3
229940049937 Pgp inhibitor Drugs 0.000 claims description 3
239000003963 antioxidant agent Substances 0.000 claims description 3
235000006708 antioxidants Nutrition 0.000 claims description 3
229940092705 beclomethasone Drugs 0.000 claims description 3
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 3
229940046731 calcineurin inhibitors Drugs 0.000 claims description 3
229960000676 flunisolide Drugs 0.000 claims description 3
229960001048 fluorometholone Drugs 0.000 claims description 3
FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims description 3
239000002748 glycoprotein P inhibitor Substances 0.000 claims description 3
230000005764 inhibitory process Effects 0.000 claims description 3
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 3
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 3
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 3
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 3
229960005294 triamcinolone Drugs 0.000 claims description 3
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 3
206010003598 Atelectasis Diseases 0.000 claims description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
208000007123 Pulmonary Atelectasis Diseases 0.000 claims description 2
230000003078 antioxidant effect Effects 0.000 claims description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
201000005202 lung cancer Diseases 0.000 claims description 2
208000020816 lung neoplasm Diseases 0.000 claims description 2
239000006199 nebulizer Substances 0.000 claims description 2
239000004031 partial agonist Substances 0.000 claims description 2
150000003431 steroids Chemical class 0.000 claims description 2
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
206010037423 Pulmonary oedema Diseases 0.000 claims 1
239000003149 muscarinic antagonist Substances 0.000 claims 1
208000005333 pulmonary edema Diseases 0.000 claims 1
239000000168 bronchodilator agent Substances 0.000 abstract description 5
102000035195 Peptidases Human genes 0.000 abstract description 2
108091005804 Peptidases Proteins 0.000 abstract description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract description 2
235000019833 protease Nutrition 0.000 abstract description 2
230000002685 pulmonary effect Effects 0.000 description 27
230000000694 effects Effects 0.000 description 26
239000003814 drug Substances 0.000 description 23
229940079593 drug Drugs 0.000 description 16
SNIBJKHIKIIGPR-UHFFFAOYSA-N N-desethyloxybutynin Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCNCC)C1CCCCC1 SNIBJKHIKIIGPR-UHFFFAOYSA-N 0.000 description 13
230000001225 therapeutic effect Effects 0.000 description 13
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
238000011282 treatment Methods 0.000 description 12
238000009472 formulation Methods 0.000 description 11
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 10
229940110309 tiotropium Drugs 0.000 description 10
241000700198 Cavia Species 0.000 description 8
206010066218 Stress Urinary Incontinence Diseases 0.000 description 8
206010006482 Bronchospasm Diseases 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
230000007885 bronchoconstriction Effects 0.000 description 7
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 7
208000023504 respiratory system disease Diseases 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
208000000921 Urge Urinary Incontinence Diseases 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
208000002551 irritable bowel syndrome Diseases 0.000 description 6
239000008101 lactose Substances 0.000 description 6
239000002207 metabolite Substances 0.000 description 6
229960002329 methacholine Drugs 0.000 description 6
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 5
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 5
206010046543 Urinary incontinence Diseases 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000037317 transdermal delivery Effects 0.000 description 5
SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 4
206010038687 Respiratory distress Diseases 0.000 description 4
238000000540 analysis of variance Methods 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
238000001061 Dunnett's test Methods 0.000 description 3
VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 3
206010021639 Incontinence Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
230000009471 action Effects 0.000 description 3
230000001078 anti-cholinergic effect Effects 0.000 description 3
230000004872 arterial blood pressure Effects 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
206010013781 dry mouth Diseases 0.000 description 3
229940015042 glycopyrrolate Drugs 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
229930010796 primary metabolite Natural products 0.000 description 3
238000011084 recovery Methods 0.000 description 3
208000022170 stress incontinence Diseases 0.000 description 3
206010046494 urge incontinence Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
ZKNJEOBYOLUGKJ-ALCCZGGFSA-N (z)-2-propylpent-2-enoic acid Chemical compound CCC\C(C(O)=O)=C\CC ZKNJEOBYOLUGKJ-ALCCZGGFSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
206010013975 Dyspnoeas Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
230000002921 anti-spasmodic effect Effects 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000036765 blood level Effects 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
239000013386 metal-inorganic framework Substances 0.000 description 2
230000004118 muscle contraction Effects 0.000 description 2
230000031990 negative regulation of inflammatory response Effects 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
229960002016 oxybutynin chloride Drugs 0.000 description 2
230000036407 pain Effects 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
238000000634 powder X-ray diffraction Methods 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
210000003079 salivary gland Anatomy 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
239000007921 spray Substances 0.000 description 2
230000035882 stress Effects 0.000 description 2
238000012916 structural analysis Methods 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000004797 therapeutic response Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
201000002909 Aspergillosis Diseases 0.000 description 1
208000036641 Aspergillus infections Diseases 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000223203 Coccidioides Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
206010061974 Gastrointestinal obstruction Diseases 0.000 description 1
201000002563 Histoplasmosis Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020853 Hypertonic bladder Diseases 0.000 description 1
206010025219 Lymphangioma Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000006550 Mydriasis Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000005119 Necrotizing Pneumonia Diseases 0.000 description 1
241000150452 Orthohantavirus Species 0.000 description 1
208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
208000011191 Pulmonary vascular disease Diseases 0.000 description 1
201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
208000034972 Sudden Infant Death Diseases 0.000 description 1
206010042440 Sudden infant death syndrome Diseases 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Chemical class C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000012387 aerosolization Methods 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
229940124748 beta 2 agonist Drugs 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
201000009267 bronchiectasis Diseases 0.000 description 1
210000003123 bronchiole Anatomy 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
230000000178 bronchoprotective effect Effects 0.000 description 1
206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940099170 ditropan Drugs 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
201000009580 eosinophilic pneumonia Diseases 0.000 description 1
229960002061 ergocalciferol Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000000446 fuel Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229940040165 gelnique Drugs 0.000 description 1
238000011554 guinea pig model Methods 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
229960005280 isotretinoin Drugs 0.000 description 1
239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000004899 motility Effects 0.000 description 1
230000008450 motivation Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
208000020629 overactive bladder Diseases 0.000 description 1
SWIJYDAEGSIQPZ-UHFFFAOYSA-N oxybutynin chloride Chemical compound [H+].[Cl-].C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 SWIJYDAEGSIQPZ-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
230000007084 physiological dysfunction Effects 0.000 description 1
206010035653 pneumoconiosis Diseases 0.000 description 1
239000012254 powdered material Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
201000008312 primary pulmonary hypertension Diseases 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
201000009732 pulmonary eosinophilia Diseases 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
201000002859 sleep apnea Diseases 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
229940042129 topical gel Drugs 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
229960002117 triamcinolone acetonide Drugs 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
239000011653 vitamin D2 Chemical class 0.000 description 1
235000001892 vitamin D2 Nutrition 0.000 description 1
239000011647 vitamin D3 Chemical class 0.000 description 1
235000005282 vitamin D3 Nutrition 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
229940021056 vitamin d3 Drugs 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP2015550444A 2012-12-27 2013-12-12 オキシブチニンを投与するための方法および組成物 Pending JP2016504358A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13/728,706 US9119777B2 (en)	2008-05-30	2012-12-27	Methods and compositions for administration of oxybutynin
US13/728,706		2012-12-27
PCT/US2013/074759 WO2014105446A1 (en)	2012-12-27	2013-12-12	Methods and compositions for administration of oxybutynin

Publications (1)

Publication Number	Publication Date
JP2016504358A true JP2016504358A (ja)	2016-02-12

Family

ID=51021931

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2015550444A Pending JP2016504358A (ja)	2012-12-27	2013-12-12	オキシブチニンを投与するための方法および組成物

Country Status (15)

Country	Link
EP (1)	EP2938329A4 (es)
JP (1)	JP2016504358A (es)
KR (1)	KR20150100902A (es)
CN (1)	CN104955444A (es)
AR (1)	AR094287A1 (es)
AU (1)	AU2013368298B2 (es)
BR (1)	BR112015015421A2 (es)
CA (1)	CA2895955A1 (es)
EA (1)	EA201591218A1 (es)
HK (2)	HK1215396A1 (es)
IL (1)	IL239623A0 (es)
MX (1)	MX2015008333A (es)
NZ (1)	NZ628479A (es)
UY (1)	UY35230A (es)
WO (1)	WO2014105446A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3421049B1 (en) *	2016-02-25	2020-07-29	Hisamitsu Pharmaceutical Co., Inc.	Liquid external preparation
CN115667205A (zh)	2020-05-05	2023-01-31	爱普宁公司(特拉华)	(r)-盐酸奥昔布宁的多晶形物形式

Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004505036A (ja) *	2000-08-02	2004-02-19	エフ．ホフマン−ラ　ロシュ　アーゲー	肺気腫の治療のための１３−ｃｉｓ−レチノイン酸の使用
JP2007536361A (ja) *	2004-05-10	2007-12-13	ソセイ・アール・アンド・ディー・リミテッド	呼吸器疾患の治療
WO2009134524A2 (en) *	2008-02-26	2009-11-05	Elevation Pharmaceuticals, Inc.	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2010147631A1 (en) *	2009-06-16	2010-12-23	Wen Tan	Use of r-bambuterol as inhaled medicament and combination therapies for treatment of respiratory disorders
WO2011048379A2 (en) *	2009-10-21	2011-04-28	Innovata Limited	Composition
WO2011120779A1 (en) *	2010-04-01	2011-10-06	Chiesi Farmaceutici S.P.A.	Process for preparing carrier particles for dry powders for inhalation
US20110253133A1 (en) *	2008-05-30	2011-10-20	Martin Michael J	Methods and compositions for administration of oxybutynin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1191930A2 (en) *	1999-05-20	2002-04-03	Sepracor Inc.	Methods for treatment of asthma using s-oxybutynin
MXPA05004584A (es) *	2002-10-29	2005-07-26	Pharmacia & Up John Company Ll	Compuestos de amonio cuaternario.
MX2007004976A (es) *	2004-10-25	2007-06-14	Schering Corp	Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios.
CA2812952A1 (en) *	2010-09-27	2012-04-12	Microdose Therapeutx, Inc.	Methods and compositions for disease treatment using inhalation

2013
- 2013-12-12 CN CN201380068230.5A patent/CN104955444A/zh active Pending
- 2013-12-12 EA EA201591218A patent/EA201591218A1/ru unknown
- 2013-12-12 KR KR1020157020335A patent/KR20150100902A/ko not_active Ceased
- 2013-12-12 CA CA2895955A patent/CA2895955A1/en not_active Abandoned
- 2013-12-12 NZ NZ628479A patent/NZ628479A/en not_active IP Right Cessation
- 2013-12-12 WO PCT/US2013/074759 patent/WO2014105446A1/en not_active Ceased
- 2013-12-12 JP JP2015550444A patent/JP2016504358A/ja active Pending
- 2013-12-12 AU AU2013368298A patent/AU2013368298B2/en not_active Ceased
- 2013-12-12 BR BR112015015421A patent/BR112015015421A2/pt not_active IP Right Cessation
- 2013-12-12 HK HK16103431.3A patent/HK1215396A1/zh unknown
- 2013-12-12 MX MX2015008333A patent/MX2015008333A/es unknown
- 2013-12-12 HK HK16104715.8A patent/HK1216843A1/zh unknown
- 2013-12-12 EP EP13867956.8A patent/EP2938329A4/en not_active Withdrawn
- 2013-12-20 UY UY0001035230A patent/UY35230A/es not_active Application Discontinuation
- 2013-12-27 AR ARP130105037A patent/AR094287A1/es unknown
2015
- 2015-06-24 IL IL239623A patent/IL239623A0/en unknown

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004505036A (ja) *	2000-08-02	2004-02-19	エフ．ホフマン−ラ　ロシュ　アーゲー	肺気腫の治療のための１３−ｃｉｓ−レチノイン酸の使用
JP2007536361A (ja) *	2004-05-10	2007-12-13	ソセイ・アール・アンド・ディー・リミテッド	呼吸器疾患の治療
WO2009134524A2 (en) *	2008-02-26	2009-11-05	Elevation Pharmaceuticals, Inc.	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20110253133A1 (en) *	2008-05-30	2011-10-20	Martin Michael J	Methods and compositions for administration of oxybutynin
WO2010147631A1 (en) *	2009-06-16	2010-12-23	Wen Tan	Use of r-bambuterol as inhaled medicament and combination therapies for treatment of respiratory disorders
WO2011048379A2 (en) *	2009-10-21	2011-04-28	Innovata Limited	Composition
WO2011120779A1 (en) *	2010-04-01	2011-10-06	Chiesi Farmaceutici S.P.A.	Process for preparing carrier particles for dry powders for inhalation

Also Published As

Publication number	Publication date
AR094287A1 (es)	2015-07-22
UY35230A (es)	2015-01-30
CA2895955A1 (en)	2014-07-03
EP2938329A4 (en)	2016-08-10
WO2014105446A1 (en)	2014-07-03
NZ628479A (en)	2016-06-24
KR20150100902A (ko)	2015-09-02
HK1215396A1 (zh)	2016-08-26
AU2013368298A1 (en)	2015-07-02
AU2013368298B2 (en)	2016-08-11
EA201591218A1 (ru)	2015-11-30
BR112015015421A2 (pt)	2017-07-11
MX2015008333A (es)	2015-11-09
EP2938329A1 (en)	2015-11-04
CN104955444A (zh)	2015-09-30
HK1216843A1 (zh)	2016-12-09
IL239623A0 (en)	2015-08-31

Publication	Publication Date	Title
TWI272106B (en)	2007-02-01	New medicament compositions based on anticholinergically-effective compounds and beta-mimetics
US20150238456A1 (en)	2015-08-27	Methods and compositions for administration of oxybutynin
CN103501776A (zh)	2014-01-08	甘罗铵与β2激动剂的组合物
JP2010539182A (ja)	2010-12-16	治療剤の新規組み合わせ
EA023839B1 (ru)	2016-07-29	Комбинации антагониста мускариновых рецепторов и агониста бета-2-адренорецепторов
JP2014516062A (ja)	2014-07-07	ウメクリジニウム及びコルチコステロイドを含む組合せ
AU2008259864C1 (en)	2014-03-06	Methods and compositions for administration of Oxybutynin
AU2015261103A1 (en)	2016-11-17	Combinations of tiotropium bromide, formoterol and budesonide for the treatment of COPD
US8748488B2 (en)	2014-06-10	Methods and compositions for administration of oxybutynin
AU2013368298B2 (en)	2016-08-11	Methods and compositions for administration of oxybutynin
WO2010097114A1 (en)	2010-09-02	Novel combination of therapeutic agents
US20120101076A1 (en)	2012-04-26	Carbonate derivatives for the treatment of cough
CA3029621A1 (en)	2018-01-04	Compositions and methods for treatment of copd
KR20050094810A (ko)	2005-09-28	로플루미래스트와 ｒ,ｒ-포르모테롤을 포함하는 상승작용성조합물
JP2013525357A (ja)	2013-06-20	多発性骨髄腫の治療のための組成物および方法
HK1232788A1 (en)	2018-01-19	Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd

Legal Events

Date	Code	Title	Description
2015-11-04	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151104
2015-11-04	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151104
2016-07-27	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160727
2016-09-12	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160912
2017-01-04	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170104